130 related articles for article (PubMed ID: 38084536)
1. The role of R21 expression in differential diagnosis of melanocytic lesions.
Turcan D; Paşaoğlu Ö; Arik D
Indian J Pathol Microbiol; 2023; 66(4):804-809. PubMed ID: 38084536
[TBL] [Abstract][Full Text] [Related]
2. Expression of soluble adenylyl cyclase in lentigo maligna: use of immunohistochemistry with anti-soluble adenylyl cyclase antibody (R21) in diagnosis of lentigo maligna and assessment of margins.
Magro CM; Yang SE; Zippin JH; Zembowicz A
Arch Pathol Lab Med; 2012 Dec; 136(12):1558-64. PubMed ID: 23194049
[TBL] [Abstract][Full Text] [Related]
3. The usefulness of c-Kit in the immunohistochemical assessment of melanocytic lesions.
Pilloni L; Bianco P; Difelice E; Cabras S; Castellanos ME; Atzori L; Ferreli C; Mulas P; Nemolato S; Faa G
Eur J Histochem; 2011 Jun; 55(2):e20. PubMed ID: 22193299
[TBL] [Abstract][Full Text] [Related]
4. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions.
Nasr MR; El-Zammar O
Am J Dermatopathol; 2008 Apr; 30(2):117-22. PubMed ID: 18360113
[TBL] [Abstract][Full Text] [Related]
5. Nucleolar organizer regions argyrophilic associated proteins in cutaneous melanocytic lesions.
Reis JP; Tellechea O; Baptista AP
Dermatologica; 1991; 183(2):136-8. PubMed ID: 1743375
[TBL] [Abstract][Full Text] [Related]
6. [Comparative study of HMB-45 monoclonal antibody uptake on various benign and malignant melanocytic lesions].
Lampert A; Thomine E; Lauret P; Hemet J
Ann Pathol; 1993; 13(2):100-7. PubMed ID: 8363667
[TBL] [Abstract][Full Text] [Related]
7. PRAME expression in melanocytic proliferations with intermediate histopathologic or spitzoid features.
Raghavan SS; Wang JY; Kwok S; Rieger KE; Novoa RA; Brown RA
J Cutan Pathol; 2020 Dec; 47(12):1123-1131. PubMed ID: 32700786
[TBL] [Abstract][Full Text] [Related]
8. Minichromosome maintenance protein expression in benign nevi, dysplastic nevi, melanoma, and cutaneous melanoma metastases.
Boyd AS; Shakhtour B; Shyr Y
J Am Acad Dermatol; 2008 May; 58(5):750-4. PubMed ID: 18249467
[TBL] [Abstract][Full Text] [Related]
9. Atypical melanocytic nevi of the genital type with a discussion of reciprocal parenchymal-stromal interactions in the biology of neoplasia.
Clark WH; Hood AF; Tucker MA; Jampel RM
Hum Pathol; 1998 Jan; 29(1 Suppl 1):S1-24. PubMed ID: 9445124
[TBL] [Abstract][Full Text] [Related]
10. p16 expression: a marker of differentiation between childhood malignant melanomas and Spitz nevi.
Al Dhaybi R; Agoumi M; Gagné I; McCuaig C; Powell J; Kokta V
J Am Acad Dermatol; 2011 Aug; 65(2):357-363. PubMed ID: 21550132
[TBL] [Abstract][Full Text] [Related]
11. High expression of cytoplasmic phosphorylated CSE1L in malignant melanoma but not in benign nevi: phosphorylated CSE1L for the discrimination between melanoma and benign nevi.
Chin SY; Wu PR; Shih YH; Yeh CM; Lee WR; Shen SC; Yeh KT; Jiang MC; Tseng JT
Int J Clin Exp Pathol; 2015; 8(2):1393-401. PubMed ID: 25973023
[TBL] [Abstract][Full Text] [Related]
12. Soluble adenylyl cyclase antibody profile as a diagnostic adjunct in the assessment of pigmented lesions.
Magro CM; Crowson AN; Desman G; Zippin JH
Arch Dermatol; 2012 Mar; 148(3):335-44. PubMed ID: 22105816
[TBL] [Abstract][Full Text] [Related]
13. Refining the application of PRAME-a useful marker in high CSD and acral melanoma subtypes.
Wakefield C; O'Keefe L; Heffron CCBB
Virchows Arch; 2023 Dec; 483(6):847-854. PubMed ID: 37723345
[TBL] [Abstract][Full Text] [Related]
14. [Application of immunohistochemical staining of PRAME in differential diagnosis between melanoma and melanocytic nevus].
Du J; Yu WJ; Guo RP; Su J
Zhonghua Bing Li Xue Za Zhi; 2022 Jul; 51(7):621-626. PubMed ID: 35785832
[No Abstract] [Full Text] [Related]
15. Common acquired melanocytic nevi, melanocytic dysplasia and malignant melanoma. A morphometric study.
Santucci M; Urso C; Giannini A; Bondi R
Appl Pathol; 1989; 7(2):111-5. PubMed ID: 2730799
[TBL] [Abstract][Full Text] [Related]
16. hTERT expression in melanocytic lesions: an immunohistochemical study on paraffin-embedded tissue.
Fullen DR; Zhu W; Thomas D; Su LD
J Cutan Pathol; 2005 Nov; 32(10):680-4. PubMed ID: 16293180
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical Expression of p16 in Melanocytic Lesions: An Updated Review and Meta-analysis.
Koh SS; Cassarino DS
Arch Pathol Lab Med; 2018 Jul; 142(7):815-828. PubMed ID: 29939777
[TBL] [Abstract][Full Text] [Related]
18. Cyclin D1 and D3 expression in melanocytic skin lesions.
Alekseenko A; Wojas-Pelc A; Lis GJ; Furgał-Borzych A; Surówka G; Litwin JA
Arch Dermatol Res; 2010 Sep; 302(7):545-50. PubMed ID: 20496072
[TBL] [Abstract][Full Text] [Related]
19. IMP-3 is a novel progression marker in malignant melanoma.
Pryor JG; Bourne PA; Yang Q; Spaulding BO; Scott GA; Xu H
Mod Pathol; 2008 Apr; 21(4):431-7. PubMed ID: 18204432
[TBL] [Abstract][Full Text] [Related]
20. Importance of P-cadherin, beta-catenin, and Wnt5a/frizzled for progression of melanocytic tumors and prognosis in cutaneous melanoma.
Bachmann IM; Straume O; Puntervoll HE; Kalvenes MB; Akslen LA
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8606-14. PubMed ID: 16361544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
